Pyruvate dehydrogenase (lipoamide) E1 subunit (PDH E1) (PDH E1)

The Pyruvate dehydrogenase (E1) subunit is the rate-limiting component of the mitochondrial Pyruvate Dehydrogenase Complex (PDC), which converts pyruvate into acetyl-CoA (UniProt: P08559). This enzyme utilizes thiamine pyrophosphate (TPP) as an essential cofactor at its active site to perform the oxidative decarboxylation of pyruvate, bridging the gap between anaerobic glycolysis and the aerobic citric acid cycle (PubMed: PMID 23103333). Genetic mutations in the E1 subunit, particularly in the PDHA1 gene, are the primary cause of Pyruvate Dehydrogenase Deficiency, a condition characterized by chronic lactic acidosis and severe neurological impairment such as Leigh syndrome (StatPearls: Pyruvate Dehydrogenase Complex Deficiency). In oncology, the E1 subunit is a target for metabolic reprogramming; many tumors downregulate its activity to favor glycolysis (the Warburg effect), and therapeutic reactivation is being explored to induce apoptosis in cancer cells (PubMed: PMID 25659581). Pharmacological agents targeting this site include thiamine and its lipophilic derivatives like benfotiamine, which enhance enzyme activity by ensuring cofactor availability (PubChem). Additionally, drugs like dichloroacetate indirectly support E1 function by inhibiting the kinases that normally inactivate the subunit through phosphorylation (PubMed: PMID 18439548). Research also explores small molecule inhibitors of the E1 subunit to disrupt the metabolic flexibility of resistant tumor cells.

Other names

Pyruvate dehydrogenase (acetyl-transferring)PDHE1PDHA1PDHBPyruvate decarboxylaseE1 subunit of the pyruvate dehydrogenase complex

Cofactor supplementation to the thiamine pyrophosphate (TPP) binding site, and indirect activation via inhibition of regulatory kinases (PDKs) to maintain the E1 subunit in its active dephosphorylated state.